The slowdown came fast, steadily, and relentlessly, as seen in Intuitives subsequent quarterly commentary: Q323: In bariatrics, we continued to see double digit growth albeit at a modestly lower growth rate compared to Q2 Q423: We saw a continued deceleration in growth throughout 2023, likely the result of the uptake of GLP-1 drugs. Q124: Bariatric procedure growth continued to moderate and was flat year-over-year
Towards general integration After seven years of integration efforts, the picture is beginning to change to a more consistent mosaic
Guess how many FDA approved medications we have
Accessed on 31 Aug 2023
A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains
The Hisayama longitudinal study evaluated the total brain, intracranial, and hippocampal volumes of 1238 subjects over a period of 15 years